2-氯-n-(5-环丙基-1H-吡唑-3-基)-噻吩并[3,2-d]嘧啶-4-胺 | 852443-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 2-氯-n-(5-环丙基-1H-吡唑-3-基)-噻吩并[3,2-d]嘧啶-4-胺
• 英文名称: 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)thieno[3,2-d]pyrimidin-4-amine
• 英文别名: 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-Thieno[3,2-d]pyrimidin-4-amine
• CAS: 852443-70-0
• 化学式: C₁₂H₁₀ClN₅S
• 分子量: 291.764
• InChiKey: BFRAOYYFLHGBAR-UHFFFAOYSA-N

物化性质

• 密度：
  1.648±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  94.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-氯-n-(5-环丙基-1H-吡唑-3-基)-噻吩并[3,2-d]嘧啶-4-胺 在 盐酸 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 24.67h， 生成 2-(4-aminopiperidin-1-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)thieno[3,2-d]pyrimidin-4-amine
  参考文献：
  名称：

  Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors

  摘要：

  The p21-activated kinases (PAKs) play important roles in cytoskeletal organization, cellular morphogenesis, and survival and have generated significant attention as potential therapeutic targets for cancer. Following a high-throughput screen, we identified an aminopyrazole scaffold-based series that was optimized to yield group I selective PAK inhibitors. A structure-based design effort aimed at targeting the ribose pocket for both potency and selectivity led to much-improved group I vs II selectivity. Early lead compounds contained a basic primary amine, which was found to be a major metabolic soft spot with in vivo clearance proceeding predominantly via N-acetylation. We succeeded in identifying replacements with improved metabolic stability, leading to compounds with lower in vivo rodent clearance and excellent group I PAK selectivity.

  DOI：

  10.1021/acs.jmedchem.5b00572
• 作为产物：
  描述：

  2,4-二氯噻吩并[3,2-D]嘧啶 、 3-氨基-5-环丙基-1H-吡唑 在 三乙胺 作用下， 反应 24.0h， 以69%的产率得到2-氯-n-(5-环丙基-1H-吡唑-3-基)-噻吩并[3,2-d]嘧啶-4-胺
  参考文献：
  名称：

  [EN] PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES
  [FR] DERIVES DE PYRAZOLE EN TANT QU'INHIBITEURS DE RECEPTEUR TYROSINE KINASES

  摘要：

  化合物的化学式（I）及其在抑制Trk活性中的应用被描述。

  公开号：

  WO2005049033A1

文献信息

• Pyrazole derivatives as inhibitors of receptor tyrosone kinases
  申请人：Block Howard Michael

  公开号：US20070142413A1

  公开（公告）日：2007-06-21

  Compounds of formula (I): and their use in the inhibition of Trk activity are described.

  描述了式(I)的化合物及其在抑制Trk活性方面的用途。
• HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Bhattacharya Samit Kumar

  公开号：US20090281073A1

  公开（公告）日：2009-11-12

  This invention relates to compounds of Formula (I), and to pharmaceutically acceptable salts and solvates thereof, wherein Z, W, X, Y, V, R 1 , R 2 , and R 3 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of Formula (I) and to pharmaceutical compositions for treating such disorders which contain the compounds of Formula (I). The invention also relates to methods of preparing the compounds of Formula (I).

  本发明涉及公式(I)的化合物，以及其药学上可接受的盐和溶剂化物，其中Z，W，X，Y，V，R1，R2和R3的定义如本文所述。该发明还涉及通过给予公式(I)的化合物来治疗哺乳动物中的异常细胞生长的方法，以及含有公式(I)的化合物用于治疗这种疾病的药物组合物。该发明还涉及制备公式(I)的化合物的方法。
• PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
  申请人：Block Michael Howard

  公开号：US20100152219A1

  公开（公告）日：2010-06-17

  Compounds of formula (I): and their use in the inhibition of Trk activity are described.

  描述了式(I)的化合物及其在抑制Trk活性方面的应用。
• 피리미딘 및 트리아진 유도체, 이의 제조방법 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
  申请人：에이치케이이노엔 주식회사

  公开号：KR20240026309A

  公开（公告）日：2024-02-28

  본 발명은 피리미딘 및 트리아진 유도체, 이의 제조방법 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물에 관한 것으로서, 상기 유도체는 Fer 키나아제 활성을 저해할 수 있어 Fer 키나아제가 관여하는 다양한 암의 예방 또는 치료에 효능을 나타낼 수 있고, 특히 저항성 극복을 통한 항암활성 측면에서 우수한 효과를 나타내기 때문에 항암제로 유용하게 사용될 수 있다.

  本发明涉及嘧啶及三嗪衍生物、其制备方法，以及包含上述衍生物的用于癌症预防或治疗的药用组合物。上述衍生物可以抑制Fer激酶活性，因此在预防或治疗涉及Fer激酶的各种癌症时具有功效；特别是在克服耐药性方面表现出优异的抗肿瘤活性，因此可作为抗肿瘤药物得到有效利用。
• WO2007/23382
  申请人：——

  公开号：——

  公开（公告）日：——